Perioperative DCF chemotherapy protocol for patients with gastroesophageal adenocarcinoma: Correlation between response to treatment and outcome

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Alcindor, T ^a   Ferri, L E ^a   Marcus, V ^a   Andalib, A ^a   Hickeson, M ^a   Artho, G ^a   Chasen, M ^b   Thirlwell, M P ^a   Ades, S ^c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer; Chemotherapy; Esophageal; Gastric; Gastroesophageal; Outcome

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLON ADENOCARCINOMA; ESOPHAGEAL ADENOCARCINOMA; FEMALE; GASTROESOPHAGEAL ADENOCARCINOMA; HUMAN; HUMAN TISSUE; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANK SUM TEST; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR REGRESSION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; STOMACH NEOPLASMS; TAXOIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84871580018     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0377-7     Document Type: Article

References (12)

1. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New Engl J Med. 2006;355:11-20.
2. Ychou M, Boige Vr, Pignon JP. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715-21.
3. Ferri LE, Ades S, Alcindor T, et al. Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial. Ann Oncol. 2012;23:1512-7.
4. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521-30.
5. Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol. 2003;21:4604-10.
6. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797-805.
7. Gaca J, Petersen R, Peterson B, et al. Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma. Ann Surg Oncol. 2006;13:340-6.
8. Mansour J, Tang L, Shah M, et al. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol. 2007;14:3412-8.
9. Kauppi JT, Oksala N, Salo JA, et al. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by [18F]FDG-PET/CT. Acta Oncol. 2012;51:636-44.
10. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the Esophagogastric junction. J Clin Oncol. 2006;24:4692-8.
11. Meyer zum Büschenfelde C, Herrmann K, Schuster T et al. 18F-FDG PETΓÇôGuided Salvage Neoadjuvant Radiochemotherapy of Adenocarcinoma of the Esophagogastric Junction: The MUNICON II Trial. J Nuclear Med 2011; 52: 1189-1196.
12. Shitara K, Ikeda J, Yokota T et al. Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials. Invest New Drugs 2011; 1-8.